Quick Answer
GRI Bio, Inc. reported Operating Income Loss of -$11.98 million for the year ending 2025.
- GRI Bio, Inc. showed a decrease of -45.4% in Operating Income Loss from 2024 to 2025.
- This data is from GRI Bio, Inc.'s annual report (Form 10-K), filed with the SEC on January 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.16 million | Q2 2020: -$1.14 million | Q3 2020: -$1.03 million | Q1 2021: -$2.60 million | Q2 2021: -$2.31 million | Q3 2021: -$1.25 million | Q1 2022: -$2.63 million | Q2 2022: -$189.0 thousand | Q3 2022: -$186.0 thousand | Q1 2023: -$988.0 thousand | Q2 2023: -$5.93 million | Q3 2023: -$2.44 million | Q1 2024: -$1.90 million | Q2 2024: -$2.26 million | Q3 2024: -$2.13 million | Q1 2025: -$3.05 million | Q2 2025: -$2.90 million | Q3 2025: -$3.37 million.
- Over the full 6 years of available data (2020 to 2025), GRI Bio, Inc.'s Operating Income Loss has declined by 150.1%.
- Historical annual values: Fiscal year 2025: -$11.98 million | Fiscal year 2024: -$8.24 million | Fiscal year 2023: -$11.39 million | Fiscal year 2022: -$2.24 million | Fiscal year 2021: -$9.26 million | Fiscal year 2020: -$4.79 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: